Want to see HK:1672 full AI Analyst Report?
Ascletis Pharma, Inc. (1672) Ratios
Ascletis Pharma, Inc. Ratios
HK:1672's free cash flow for Q2 2026 was $-295.32M. For the 2026 fiscal year, HK:1672's free cash flow was decreased by $-1.31M and operating cash flow was $-294.01M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 15.05 | 12.88 | 16.58 | 23.52 | 28.93 |
| Quick Ratio | 15.04 | 12.85 | 16.54 | 23.33 | 28.31 |
| Cash Ratio | 11.31 | 5.66 | 2.35 | 22.84 | 27.43 |
| Solvency Ratio | -2.63 | -1.81 | -0.85 | -2.43 | -1.68 |
| Operating Cash Flow Ratio | -2.58 | -2.23 | -1.02 | -1.32 | -1.62 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 1.79B | $ 1.81B | $ 2.18B | $ 2.43B | $ 2.53B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.07 | 1.08 | 1.06 | 1.05 | 1.04 |
| Debt Service Coverage Ratio | -2850.13 | 0.00 | -875.63 | -2142.45 | -1379.74 |
| Interest Coverage Ratio | -2949.74 | 0.00 | -2084.78 | -2190.94 | -1799.73 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Net Debt to EBITDA | 3.08 | 2.20 | 2.55 | 8.67 | 14.72 |
| Profitability Margins | |||||
| Gross Profit Margin | 25.99% | 57.29% | 45.92% | -45.65% | 50.96% |
| EBIT Margin | -23892.11% | -31538.04% | -255.44% | -581.78% | -258.72% |
| EBITDA Margin | -23023.42% | -30432.58% | -222.79% | -525.97% | -220.29% |
| Operating Profit Margin | -23853.94% | -23025.64% | -530.44% | -635.94% | -292.63% |
| Pretax Profit Margin | -17720.61% | -23455.65% | -255.70% | -582.07% | -258.88% |
| Net Profit Margin | -17745.56% | -23455.65% | -255.70% | -582.07% | -258.88% |
| Continuous Operations Profit Margin | -17745.56% | -23455.65% | -255.70% | -582.07% | -258.88% |
| Net Income Per EBT | 100.14% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 74.29% | 101.87% | 48.20% | 91.53% | 88.47% |
| Return on Assets (ROA) | -17.41% | -14.16% | -5.81% | -11.85% | -7.03% |
| Return on Equity (ROE) | -18.60% | -15.31% | -6.18% | -12.40% | -7.29% |
| Return on Capital Employed (ROCE) | -24.94% | -14.98% | -12.77% | -13.50% | -8.21% |
| Return on Invested Capital (ROIC) | -24.90% | -14.94% | -12.74% | -13.48% | -8.21% |
| Return on Tangible Assets | -17.49% | -14.25% | -5.87% | -11.92% | -7.23% |
| Earnings Yield | -3.62% | -10.63% | -11.44% | -6.92% | -6.77% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.15 | 8.44 | 10.42 | 2.27 | 1.43 |
| Payables Turnover | 1.12 | 17.68 | 47.16 | 25.13 | 35.77 |
| Inventory Turnover | 0.80 | 0.13 | 5.04 | 3.84 | 0.67 |
| Fixed Asset Turnover | 0.04 | 0.02 | 0.83 | 0.74 | 0.99 |
| Asset Turnover | 0.00 | 0.00 | 0.02 | 0.02 | 0.03 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.02 | 0.02 | 0.03 |
| Cash Conversion Cycle | 2509.11 | 2935.27 | 99.69 | 241.64 | 788.70 |
| Days of Sales Outstanding | 2380.18 | 43.24 | 35.03 | 161.10 | 254.52 |
| Days of Inventory Outstanding | 455.90 | 2912.67 | 72.40 | 95.07 | 544.39 |
| Days of Payables Outstanding | 326.96 | 20.65 | 7.74 | 14.52 | 10.20 |
| Operating Cycle | 2836.07 | 2955.92 | 107.43 | 256.16 | 798.90 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.34 | -0.34 | -0.13 | -0.13 | -0.13 |
| Free Cash Flow Per Share | -0.34 | -0.34 | -0.15 | -0.14 | -0.14 |
| Dividend Paid and CapEx Coverage Ratio | -205.70 | -159.02 | -7.52 | -9.89 | -20.41 |
| Capital Expenditure Coverage Ratio | -205.70 | -159.02 | -7.52 | -9.89 | -20.41 |
| Operating Cash Flow Coverage Ratio | -63.80 | -44.75 | -17.13 | -33.62 | -53.43 |
| Operating Cash Flow to Sales Ratio | -162.34 | -266.23 | -2.55 | -2.63 | -1.91 |
| Free Cash Flow Yield | -3.33% | -12.14% | -12.91% | -3.45% | -5.24% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -27.65 | -9.41 | -8.74 | -14.45 | -14.78 |
| Price-to-Sales (P/S) Ratio | 4905.96 | 2206.93 | 22.36 | 84.11 | 38.26 |
| Price-to-Book (P/B) Ratio | 5.14 | 1.44 | 0.54 | 1.79 | 1.08 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -30.07 | -8.24 | -7.75 | -29.01 | -19.08 |
| Price-to-Operating Cash Flow Ratio | -30.22 | -8.29 | -8.78 | -31.94 | -20.02 |
| Price-to-Earnings Growth (PEG) Ratio | -1.18 | -0.07 | 0.16 | -0.24 | 1.48 |
| Enterprise Value Multiple | -18.23 | -5.05 | -7.48 | -7.32 | -2.65 |
| Enterprise Value | 8.51B | 1.97B | 943.53M | 2.08B | 448.16M |
| EV to EBITDA | -18.23 | -5.05 | -7.48 | -7.32 | -2.65 |
| EV to Sales | 4196.41 | 1538.11 | 16.67 | 38.51 | 5.83 |
| EV to Free Cash Flow | -25.72 | -5.74 | -5.78 | -13.28 | -2.91 |
| EV to Operating Cash Flow | -25.85 | -5.78 | -6.54 | -14.62 | -3.05 |
| Tangible Book Value Per Share | 1.98 | 1.95 | 2.16 | 2.32 | 2.42 |
| Shareholders’ Equity Per Share | 1.99 | 1.96 | 2.18 | 2.34 | 2.49 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | 0.00 | 0.00 | -0.16 | -0.02 |
| Revenue Per Share | 0.00 | 0.00 | 0.05 | 0.05 | 0.07 |
| Net Income Per Share | -0.37 | -0.30 | -0.13 | -0.29 | -0.18 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.74 | 0.74 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 201.70 | 235.69 | 3.83 | 4.94 | 2.77 |
| SG&A to Revenue | 37.10 | 79.30 | 1.11 | 0.29 | 0.21 |
| Stock-Based Compensation to Revenue | 3.76 | 2.34 | 0.02 | 0.06 | 0.09 |
| Income Quality | 0.92 | 1.14 | 1.00 | 0.45 | 0.74 |
Currency in CNY
